Combination of medication of containing kurarinone and glycyrrhetic acid, and application

A composition, the technology of matrine, applied in the pharmaceutical composition containing matrine and glycyrrhizic acid and its application field, can solve the problems of poor prognosis, inaccurate clinical curative effect, unacceptable by patients, etc.

Inactive Publication Date: 2005-11-16
JIANGSU HENGRUI MEDICINE CO LTD
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Its etiology and pathogenesis are extremely complex, and there is no definite and effective drug for its prevention and treatment.
In clinical practice, TCM syndrome differentiation is often used, and some auxiliary drugs are added to improve the curative effect, but the prognosis of many patients is very poor, which brings adverse effects to society and family
[0003] Matrine has a certain anti-hepatitis virus and liver protection effect, and has been used clinically to treat chronic hepatitis, but the clinical curative effect of the effective extract of matrine or matrine is not accurat...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Example 1: Immune mouse liver injury model induced by Concanavalin A (Con-A)

[0036] Animals: 1) Kunming mice, male, 18-22 g, provided by the Animal Experimental Breeding Farm of the Chinese Academy of Medical Sciences.

[0037] License number: SCXK11-00-0006.

[0038] 2) ICR mice: male, weighing 20-24g, provided by Weitong Lihua Laboratory Animal Technology Co., Ltd., certificate: SCXK (Beijing) 2002-0003

[0039] Samples: The test drugs matrine and glycyrrhizin were prepared to the required concentrations with normal saline for injection.

[0040] Male Kunming mice were randomly divided into normal control group, model control group and test drug group, with 12 mice in each group.

[0041] Except for the normal control group, the model control group and the test drug group were intraperitoneally injected (ip) with the corresponding physiological saline or test drug once in the afternoon of the first day, the morning of the next day, and the afternoon of the next da...

Embodiment 2

[0046] Example 2: The protective effect of different ratio compositions of matrine and glycyrrhizin on immune liver injury caused by concanavalin A (Con-A)

[0047] In this example, the immune mouse liver injury model caused by concanavalin A (Con-A) was used to observe the effect of different formulations of matrine and glycyrrhizin with a total dose of 190 mg / kg on the effects of ConA. The mice have obvious protective effect on liver injury.

[0048] The experimental method and ConA model used were the same as those in Example 1, and 12 male Kunming mice were tested in each group. Judging from the reduction of transaminase activity, the 2:1 drug combination of matrine:glycyrrhizin or the 1:4 drug combination of matrine and glycyrrhizin has significantly better effect on reducing the activities of ALT and AST than using Sophora flavescens alone of glycyrrhizin or glycyrrhizin.

[0049] Compared with the ConA model group, it can be seen that the different ratio compositions ...

Embodiment 3

[0052] Example 3: Paracetamol (PHAA)-induced liver injury model in mice

[0053] Male Kunming mice were randomly divided into normal control group, model control group and test drug group, with 12 mice in each group. Except for the normal control group, the model control group and the test drug group were given intraperitoneal injection (ip) of the corresponding normal saline or test drug once in the afternoon of the first day, the morning of the next day, and the afternoon of the next day, and one hour after the last administration. , the corresponding concentration of 185mg / kg paracetamol 20ml / kg intraperitoneal injection. The animals were fasted overnight, 16 hours later, the animals were killed by decapitation, blood was collected to separate serum, and the activities of alanine aminotransferase (ALT) and alanine aminotransferase (AST) in serum were determined according to the kit instructions.

[0054] Compared with the paracetamol model group, it can be seen that the di...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A composite medicine or its medicinal kit for preventing and treating hepatitis B, hepatitis B, hepatitis C, AIDS and tumor features that its contains kurarinol (or kurarinol oxide) and glycyrrhizic acid, or their pharmacological acceptable salts.

Description

technical field [0001] The present invention relates to a kind of pharmaceutical composition and application thereof, and described pharmaceutical composition contains matrine and glycyrrhizic acid or their pharmaceutically acceptable form or their pharmaceutically acceptable salt, and this pharmaceutical composition is used for preparing Application in medicines for preventing and treating hepatitis or diseases related to hepatitis, especially for preventing and treating hepatitis B. Background technique [0002] Liver disease is a frequently-occurring and common disease in our country. Its etiology and pathogenesis are extremely complex, and there is no definite and effective drug for its prevention and treatment. Traditional Chinese medicine is often used in clinical treatment based on syndrome differentiation, and some auxiliary drugs are added to improve the curative effect. However, the prognosis of many patients is very poor, which brings adverse effects to society a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/56
Inventor 孙飘扬袁开红
Owner JIANGSU HENGRUI MEDICINE CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap